Netherlands-based Royal Philips has received 510(k) approval from the US Food and Drug Administration (FDA) for its IQon Spectral CT.


The new CT system has been developed in collaboration with clinicians to solve some of their most immediate challenges, including workflow and image management issues, said Philips.

Similar to the principle behind a prism splitting white light into the rainbow of colors, the new system’s technology can discriminate between X-ray photons of multiple high and low energies.

Clinicians can access the conventional grey-scale anatomical images, along with the spectral information within the same scan, through the Spectral CT scan.

Philips Healthcare Imaging Systems CEO Gene Saragnese said: "The IQon Spectral CT represents our commitment to leading a new, higher standard for medical imaging that is driven by clinical insights and focused on the patient experience.

"Delivering an additional level of spectral information without impacting clinician workflow is vital for confident diagnoses that can significantly add value to help improve patient care."

According to Philips, the new CT system is currently available for sale in around 36 countries. It will be exhibited at the upcoming Radiological Society of North America Annual Meeting (RSNA) that will be held from 30 November to 5 December in Chicago.

CT imaging is mostly used in the diagnosis of many different diseases and injuries, due to its accessibility, speed and accuracy.

Image: Philips receives FDA 510(k) clearance for IQon Spectral CT. Photo: courtesy of Royal Philips/ PRNewswire.